Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
HUMA Stock Chart & Stats
$1.12
-$0.19(-4.01%)
At close: 4:00 PM EST
$1.12
-$0.19(-4.01%)
Day’s Range― - ―
52-Week Range$0.88 - $3.49
Previous CloseN/A
Volume1.64M
Average Volume (3M)5.43M
Market Cap
$215.19M
Enterprise Value$169.58M
Total Cash (Recent Filing)$19.49M
Total Debt (Recent Filing)$29.82M
Price to Earnings (P/E)―
Beta2.59
Next Earnings
Mar 26, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding192,996,500
10 Day Avg. Volume4,283,717
30 Day Avg. Volume5,425,330
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)-11.36
Price to Sales (P/S)0.00
P/FCF Ratio-6.00
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue19.27
Enterprise Value/Gross Profit194.25
Enterprise Value/Ebitda-8.95
Forecast
1Y Price Target
$6.50Price Target Upside480.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$23.48M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And AdoptionGrowing clinical experience with ATEV shows durable outcomes, low infection rates, and no documented immune rejection, which could shift practice patterns and drive broader hospital adoption.
Defense Procurement PathwayAnalyst notes the FY2026 DoD Appropriations Act creates a clear pathway for evaluation and procurement of biologic vascular repair technologies, potentially enabling early Symvess adoption in military combat care.
Product DifferentiationSymvess's position as the only human-derived biologic vascular repair product makes it a natural candidate for situations where autologous vein harvesting is not feasible, supporting use in trauma and vascular surgery settings.
Bears Say
Financing And Dilution RiskNew credit facility and other financing activity increased share count and led to issuance of additional shares, raising dilution risk for existing shareholders and pressuring per-share metrics.
Procurement Authorization HurdlesLarge-scale or multiyear military purchases would require additional congressional authorization and committee approvals, which could limit immediate substantial orders and constrain revenue growth from defense channels.
Valuation Pressure From Analyst UpdatesAnalyst trimmed the price target after updating valuation assumptions to reflect financing activity and a higher share count, indicating reduced upside under the current capital structure.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $0.88 and its highest was $3.49 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $215.19M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Mar 26, 2026 which is in 24 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Nov 12, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.151 by $0.041.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.13.
How many shares outstanding does Humacyte have?
Humacyte has 192,996,500 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.151. Following the earnings report the stock price went down -2.344%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humacyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (480.36% Upside)
$6.50 (480.36% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 52.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.26%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
HUMA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive developments, including a significant increase in product sales, expansion of hospital approvals, positive long-term results for Symvess, a strong financial performance with reduced net loss, successful fundraising, and expansion of intellectual property. However, challenges remain with increased administrative expenses and some resistance in the hospital VAC process due to budget constraints.View all HUMA earnings summariesHUMA Stock 12 Month Forecast
Average Price Target
$6.50
▲(480.36% Upside)
Technical Analysis
Cartesian Therapeutics
―
Allogene Therapeutics
―
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
11.39% Insiders
5.61% Mutual Funds
0.80% Other Institutional Investors
74.16% Public Companies and
Individual Investors